LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday

LENZ Therapeutics (NASDAQ:LENZ) will likely be releasing its earnings data before the market opens on Wednesday, February 5th. Analysts expect LENZ Therapeutics to post earnings of ($0.41) per share for the quarter.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. During the same period last year, the company posted ($1.33) earnings per share. On average, analysts expect LENZ Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

LENZ Therapeutics Trading Up 6.4 %

Shares of LENZ Therapeutics stock opened at $26.25 on Wednesday. The firm’s 50-day moving average price is $30.21 and its two-hundred day moving average price is $26.70. LENZ Therapeutics has a 12-month low of $14.42 and a 12-month high of $38.93.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, November 7th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.